Breast Cancer Whole Genome Analysis
Whole genome analysis examines the complete genetic material of breast cancer cells, identifying mutations, structural variations, and other genomic alterations that contribute to tumor development and progression. Alfa Cytology offers a comprehensive suite of breast cancer whole genome analysis services for our clients.
Introduction of Whole Genome
Breast cancer (BC) is a global disease with the highest incidence among female malignant tumors. With the advancement of tumor molecular biology research, it has been found that the pathogenesis of BC is complex and involves changes in multiple signaling pathways. In order for patients to receive the right treatment at the right time, whole genome sequencing (WGS) has become an important clinical detection method. WGS is the sequencing of the entire genome sequence of an organism to obtain complete genome information. With its technical principles and detection range as its main advantages, WGS has demonstrated strong application value in different scenarios such as genetic diagnosis of genetic diseases, tumor gene detection, and individualized drug research. Compared with other techniques, WGS has better diagnostic efficiency, detection sensitivity, and accuracy.
Fig.1 WGS service process.
Our Services
Alfa Cytology can provide you with breast tumor genome-wide analysis services. The molecular mechanism of BC is very complex, and WGS can help in prediction, diagnosis, finding therapeutic targets, and analyzing prognostic factors. Our services include:
- Whole genome sequencing of BC
From the extraction of high-purity DNA, to library construction, on-machine sequencing, and data analysis, we can provide you with high-quality and comprehensive whole-genome sequencing services for BC tumors. You can also choose whole exome sequencing or target region capture sequencing, and our customized sequencing services will surely meet your needs. - Genetic testing for BC genetic risk
The most important inherited genetic changes in BC are the BRCA1 and BRCA2 genes. Women with BRCA gene alterations have a greatly increased risk of developing BC. There are also mutations in some genes that are also associated with BC, such as PALB2, CHEK2, ATM, CDH1, PTEN, TP53, and so on. We can provide you with BC risk gene sequencing and analysis services, providing an important reference for the prevention and treatment of BC. - Genetic testing for targeted therapy in BC
Genetic testing for BC targeted therapy can detect mutations in the DNA of BC cells, so as to facilitate the development of targeted drugs and select targeted therapies suitable for patients. - BC prognosis evaluation gene detection
BC prognosis evaluation 21-gene detection, by detecting the expression of 16 tumor-related genes (proliferation, invasion, HER2, and hormone-related genes) and 5 internal reference genes, the detection results are quantified as recurrence scores, thus predicting the risk of long-term recurrence and the benefit of chemotherapy within 10 years.
Application Fields
- BC tumor metastasis, recurrence, and heterogeneity research
- Mechanisms of drug resistance in BC
- BC tumor susceptibility gene detection
- BC targeted drug development
Advantages of Our Services
- Advanced sequencing platform
- Rich experience in data analysis
- High-resolution and coverage
- Customizable and comprehensive service
Alfa Cytology is a leading global CRO company. Our complete, optimized, and easy-to-operate workflows provide you with fast, accurate, and reproducible results to help you achieve your research goals. We provide personalized, innovative, complete sequencing service solutions, if you are interested in learning more about our BC multi-omic analysis services, please feel free to contact us. Our professional and patient staff will get in touch with you as soon as possible.